Combination Products in Rare Disease Management

Abstract

Rare diseases affect fewer than 1 in 2,000 individuals in Europe and fewer than 200,000 patients in the United States, yet collectively they represent a major global health burden across approximately 7,000 distinct conditions. Combination products -- integrated or co-packaged combinations of drugs, biologics, devices, and digital therapeutics that function as a single product -- have emerged as the dominant therapeutic innovation model in rare disease management, where the complexity of pathophysiology often requires multi-modal intervention and where small patient populations make standalone product economics challenging. This study presents the Combination Product Rare Disease Assessment Framework (CPRDAF), evaluating five combination product categories -- drug-device combinations (DD-C), biologic-device combinations (BD-C), drug-diagnostic companion products (DDx-C), cell therapy-scaffold combinations (CT-S), and digital therapeutic-drug combinations (DT-D) -- across four rare disease contexts: lysosomal storage disorders, rare oncology, rare neurological disorders, and rare musculoskeletal conditions. Performance was scored using the Combination Product Effectiveness Score (CPES), a weighted composite of clinical efficacy (0.30), regulatory pathway efficiency (0.20), patient access (0.20), manufacturing feasibility (0.15), and safety profile (0.15). Drug-diagnostic companion products achieved the highest CPES (0.900), with the best regulatory pathway efficiency (0.920) and safety profile (0.920), supported by the mature companion diagnostic regulatory framework that enables biomarker-stratified trial designs with smaller, better-powered patient cohorts. Digital-drug combinations ranked second (0.879), leading on patient access (0.920) through remote delivery capability critical for rare disease populations dispersed across geographies. Biologic-device combinations (0.850) and cell-scaffold products (0.825) face manufacturing feasibility constraints that limit deployment despite strong clinical efficacy potential in gene therapy and regenerative medicine applications respectively.